Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06015724 · ClinicalTrials.gov registry record · Phase 2
Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
A Phase 2 study of Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer, sponsored by Georgetown University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 2
- Study locations
NCT06015724 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer that is actively recruiting participants, run by Georgetown University. The registered enrollment target is 54 participants, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06015724, a Phase 2 study of Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Georgetown University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb (nivolumab) in patients with advanced non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * How well does daratumumab and nivolumab, when given with a vaccine, control or stop these types of cancer? * How well does participants bodies handle these study drugs? * Does this combination of study drugs help participants live longer? Participants will receive daratumumab, nivolumab with KRAS vaccine and have regular tests and procedures to follow how the participants are doing on these study drugs.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Daratumumab
- BIOLOGICAL KRAS vaccine
Study Locations (2)
District of Columbia
- Georgetown Lombardi Comprehensive Cancer Center - Washington D.C.
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06015724
The ClinicalTrials.gov registry entry for NCT06015724 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (91% lower). The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT06015724 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06015724 about?
NCT06015724 is a clinical study titled "Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer". The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb (nivolumab) in patients with advanced non-small...
What is the current status of trial NCT06015724?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2024-01-31. Estimated completion is 2027-01.
What conditions does trial NCT06015724 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06015724?
The interventions under investigation include: Nivolumab (DRUG), Daratumumab (DRUG), KRAS vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06015724?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06015724 being conducted?
This trial has 2 study locations across District of Columbia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 2
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RECRUITING · Phase 2
-
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 2
-
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Pancreatic Ductal Adenocarcinoma
All registered trials for this condition
Refractory Non-Small Cell Lung Cancer
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.